Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
4 hedge funds and large institutions have $10 invested in Oncternal Therapeutics, Inc. Common Stock in 2024 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 20 closing their positions.
12.07% less ownership
Funds ownership: 12.07% → 0% (-12%)
83% less funds holding
Funds holding: 23 → 4 (-19)
95% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 20
100% less capital invested
Capital invested by funds: $471K → $10 (-$471K)
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$185K |
| 2 |
Millennium Management
New York
|
-$80.8K |
| 3 |
BlackRock
New York
|
-$52.4K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$34.2K |
| 5 |
PPW
Pasadena Private Wealth
Pasadena,
California
|
-$33K |
ONCT Hedge Fund Activity: Q4 2024 in Review
4 of the 7,608 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q4 2024, worth a combined $10 — down 100% from $471K a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of ONCT and 1 opened new positions — a net loss of 19 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Vanguard Group, exiting entirely with an estimated $185K sold.
- 4 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q4 2024, down from 23 in Q3 2024.
- Funds reported $10 of Oncternal Therapeutics, Inc. Common Stock stock for Q4 2024, down 100% quarter-over-quarter.
- 1 fund opened new Oncternal Therapeutics, Inc. Common Stock positions in Q4 2024 and 20 closed out, a net change of -19 holders.
- The largest Oncternal Therapeutics, Inc. Common Stock seller in Q4 2024 was Vanguard Group, an estimated $185K sold.
Based on aggregated 13F filings for Q4 2024.